H-group (homology)
284.1 FKBP-like
Ligands and drugs
4,301
Member domains
649
with ligand contacts (≤ 4 Å)
15.1% of members
446
with DrugDomain annotations
10.4% of members
259
with a DrugBank compound
6.0% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 284.1 belongs to X-group 284 FKBP-like, which binds 9.3 ligand superclasses per 20 proteins, broader than 84% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00864 | FK5 | Tacrolimus | 56 |
| DB00877 | RAP | Sirolimus | 27 |
| DB02042 | 1PG | 2-(2-{2-[2-(2-Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol | 8 |
| DB02888 | 001 | FKB-001 | 3 |
| DB01723 | AP1 | {3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid | 2 |
| DB02311 | DSS | Methyl Methylsulfinylmethyl Sulfide | 2 |
| DB02693 | D1D | (4S,5S)-1,2-dithiane-4,5-diol | 2 |
| DB03621 | 587 | L-709,587 | 2 |
| DB04094 | BUQ | 4-hydroxybutan-2-one | 2 |
| DB04349 | PGO | (S)-propane-1,2-diol | 2 |
| DB04456 | TAS | Arsenous acid | 2 |
| DB08520 | SB1 | (21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE | 2 |
| DB12010 | — | Fostamatinib | 2 |
| DB00160 | ALA | Alanine | 1 |
| DB00172 | PRO | Proline | 1 |
| DB00337 | — | — | 1 |
| DB00755 | REA | Tretinoin | 1 |
| DB01712 | SUB | (3R)-4-(p-toluenesulfonyl)-1,4-thiazane-3-carboxylicacid-L-phenylalanine ethyl ester | 1 |
| DB01752 | SAH | S-adenosyl-L-homocysteine | 1 |
| DB01766 | — | Beta-(2-Naphthyl)-Alanine | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| FK5 | 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN | 59 |
| CL | CHLORIDE ION | 47 |
| RAP | RAPAMYCIN IMMUNOSUPPRESSANT DRUG | 33 |
| NAmetal | SODIUM ION | 20 |
| CAmetal | CALCIUM ION | 17 |
| 12P | DODECAETHYLENE GLYCOL | 15 |
| ZNmetal | ZINC ION | 11 |
| 1PG | 2-(2-{2-[2-(2-METHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHANOL | 9 |
| MGmetal | MAGNESIUM ION | 9 |
| R27 | N'-[(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-1,20,21-trioxo-8-(prop-2-en-1-yl)-1,3,4,5,6,8,11,12,13,14,15,16,17,18,19,20,21,23,24,25,26,26a-docosahydro-7H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosin-7-ylidene]acetohydrazide | 7 |
| 861 | 3-(3,4,5-trimethoxyphenyl)propyl (2S)-1-(benzylsulfonyl)piperidine-2-carboxylate | 6 |
| CDmetal | CADMIUM ION | 6 |
| UUI | (1S,5S,6R)-10-[[3,5-bis(chloranyl)phenyl]sulfonimidoyl]-5-ethenyl-3-(pyridin-2-ylmethyl)-3,10-diazabicyclo[4.3.1]decan-2-one | 5 |
| 0BF | 8-(2-chloranylethanoyl)-4-[(5-naphthalen-1-ylfuran-2-yl)methyl]-1-thia-4,8-diazaspiro[4.5]decan-3-one | 4 |
| 60Z | (3R,4E,7E,10R,11S,12R,13S,16R,17R,24aS)-11,17-dihydroxy-10,12,16-trimethyl-3-[(2R)-1-phenylbutan-2-yl]-6,9,10,11,12,13,14,15,16,17,22,23,24,24a-tetradecahydro-3H-13,17-epoxypyrido[2,1-c][1,4]oxazacyclohenicosine-1,18,19(21H)-trione | 4 |
| 6UO | 2-[(2~{S})-1-(phenylmethyl)sulfonylpiperidin-2-yl]carbonyloxyethyl pyridine-3-carboxylate | 4 |
| 9QN | (1~{S},5~{S},6~{R})-10-[3,5-bis(chloranyl)phenyl]sulfonyl-5-(hydroxymethyl)-3-(pyridin-2-ylmethyl)-3,10-diazabicyclo[4.3.1]decan-2-one | 4 |
| A1IN3 | (2~{S},9~{S},14~{E})-2-cyclohexyl-20,23-dimethoxy-11,18-dioxa-4-azatricyclo[17.2.2.0^{4,9}]tricosa-1(22),14,19(23),20-tetraene-3,10-dione | 4 |
| D44 | N-(2-ethylphenyl)-2-(3H-imidazo[4,5-b]pyridin-2-ylsulfanyl)acetamide | 4 |
| DTT | 2,3-DIHYDROXY-1,4-DITHIOBUTANE | 4 |